BRCA1 and non-small cell lung carcinoma: In S1900A, Lung-MAP sub-study, NSCLC patients had a high genomic loss of heterozygosity or BRCA1/2 mutation, progression on platinum-based or anti-PD-(L)1 therapy, and were treated with rucaparib in monotherapy.